<DOC>
	<DOCNO>NCT00188045</DOCNO>
	<brief_summary>The aim study assesment splanchnic systemic hemodynamic effect chronic administration ( 2 month ) spironolactone propranolol , alone association alcoholic cirrhotic patient . The patient randomize 4 group ( aldactone 150 mg/day , propranolol 160 mg/day , aldactone 150 mg/day + propranolol 160 mg/day , placebo ) . Systemic splanchnic hemodynamic effect evaluate hepatic venous pressure gradient measurement 2 month treatment .</brief_summary>
	<brief_title>Hemodynamic Effects Chronic Administration Spironolactone and/or Propranolol Alcoholic Cirrhotic Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Alcoholic</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Indication transjugular hepatic biopsy alcoholic cirrhosis presence oesophageal varix ≤ stade 2 renal insufficiency natremia ≤ 135 mmol/l vasoactive treatment last month inclusion hepatocellular carcinoma positive HIV HCV patient paracentesis last week inclusion digestive bleed one last week oesophageal varix stade 3 2 red sign</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>Portal hypertension , alcoholic cirrhosis , Hepatic venous pressure gradient , hemodynamic , spironolactone , propranolol</keyword>
</DOC>